Scalper1 News
Biotech firm Pharmacyclics (PCYC) jumped 6.5% to a new high on the stock market today, after its Q4 report revealed a strong launch of its cancer drug Imbruvica. Late Thursday, the company said Imbruvica garnered $13.6 million in net sales in the quarter, drawn from just six weeks on the market since it was approved for mantle-cell lymphoma in mid-November. Analysts’ consensus was just $3 million. Nomura analyst Ian Somaiya wrote in a research Scalper1 News
Scalper1 News